The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.
The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.
GlaxoSmithKline and Verily Life Sciences form Galvani Bioelectronics.
Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.
Five people have been indicted for stealing trade secrets from GlaxoSmithKline, the Wall Street Journal reports.
Therapies aimed at drug targets that have been linked genetically to disease fare better through the drug development pipeline, researchers from GSK and elsewhere found.
The institute will develop new technologies and approaches to decode how genes are controlled and how a cell's "operating system" functions.
Originally published Oct. 3.
NEW YORK (GenomeWeb) – A team led by researchers at Cellzome, a part of GlaxoSmithKline's R&D division, has developed a thermal profiling-based method for identifying protein drug targets and measuring protein-drug binding.
A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.
In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.